KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Assets (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Assets for 16 consecutive years, with $100.4 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Assets rose 3.41% year-over-year to $100.4 billion, compared with a TTM value of $100.4 billion through Sep 2024, up 3.41%, and an annual FY2023 reading of $98.7 billion, up 1.62% over the prior year.
  • Assets was $100.4 billion for Q3 2024 at Thermo Fisher Scientific, up from $98.5 billion in the prior quarter.
  • Across five years, Assets topped out at $100.4 billion in Q3 2024 and bottomed at $58.7 billion in Q1 2020.
  • Average Assets over 5 years is $84.6 billion, with a median of $92.7 billion recorded in 2022.
  • The sharpest move saw Assets soared 40.67% in 2022, then rose 1.62% in 2023.
  • Year by year, Assets stood at $69.1 billion in 2020, then surged by 37.76% to $95.1 billion in 2021, then increased by 2.14% to $97.2 billion in 2022, then grew by 1.62% to $98.7 billion in 2023, then grew by 1.66% to $100.4 billion in 2024.
  • Business Quant data shows Assets for TMO at $100.4 billion in Q3 2024, $98.5 billion in Q2 2024, and $97.1 billion in Q1 2024.